NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF)

CUSIP: G63637139

Q3 2022 13F Holders as of 30 Sep 2022

Type / Class
Equity / SHS NEW 2022
Total 13F shares
70,252
Share change
+70,252
Total reported value
$146,000
Price per share
$2.07
Number of holders
6
Value change
+$146,000
Number of buys
6

Quarterly Holders Quick Answers

What is CUSIP G63637139?
CUSIP G63637139 identifies NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) as of Q3 2022

As of 30 Sep 2022, NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) was held by 6 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 70,252 shares. The largest 6 holders included Values First Advisors, Inc., RENAISSANCE TECHNOLOGIES LLC, Frazier Life Sciences Management, L.P., MORGAN STANLEY, ADVISOR GROUP HOLDINGS, INC., and UBS Group AG. This page lists 6 institutional shareholders reporting positions in this security for the Q3 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.